LIPEMIA OF SEPSIS
It has long been observed that when animals or humans are challenged with infectious agents or endotoxin (LPS) there are significant changes in the distribution of their circulating lipoproteins. This 'lipemia of sepsis' was initially described in the late 1950s, when patients with cholera were noted to have grossly lipemic blood and high serum levels of triglyceride. 1 Gallin et al. noted the same observation in patients experiencing polymicrobial infection, 2 and the phenomenon has since been sporadically described in the literature. Experimental studies have shown that the lipemia of sepsis is primarily due to the accumulation of very low density lipoproteins (VLDL), although other lipid moieties, including glycerol, triglycerides, and fatty acids are also elevated ( Table 1 ). 3 Our understanding of the mechanism underlying the lipemia of sepsis is in evolution. Studies suggest that after an infectious challenge there is both a decrease in the catabolism of circulating lipoproteins and an increase in lipoprotein production. 4, 5 While the specific effector molecules that trigger these alterations have not been completely elucidated, several theories have been proposed. In the mid-1980s, it was suggested that the lipemia induced by the administration of LPS was secondary to the release of cachectin, or tumor necrosis factor (TNF). [6] [7] [8] Administration of TNF, already known to mimic the physiological effects of LPS, increased the mobilization of stored body fat and increased free fatty acid turnover. 9 But, when in the early 1990s anti-TNF antibodies did not prevent lipemia in LPS-treated rats, this theory was questioned. A second theory suggested that the LPS-induced lipemia was an effect of adrenergic stimulation. 10 Nonogaki et al. found that α-adrenergic blockade, but not β-adrenergic blockade, Bacterial endotoxin (LPS) elicits dramatic responses in the host including elevated plasma lipid levels due to the increased synthesis and secretion of triglyceride (TG)-rich lipoproteins by the liver, and the inhibition of lipoprotein lipase. This cytokine-induced hyperlipoproteinemia, clinically termed the 'lipemia of sepsis', was customarily thought to represent the mobilization of lipid stores to fuel the host response to infection. However, since lipoproteins can also bind and neutralize LPS, we hypothesize that TG-rich lipoproteins (VLDL and chylomicrons) are also components of an innate, non-adaptive host immune response to infection. Herein we review data demonstrating the capacity of lipoproteins to bind LPS, protect against LPS-induced toxicity, and modulate the overall host response to this bacterial toxin. Lastly, we propose a pathway whereby lipoprotein-bound LPS may represent a novel, endogenous mechanism for regulating the hepatic acute phase response. resulted in the absence of LPS-induced lipemia, suggesting a non-TNF-mediated process. At present, the lipemia of sepsis appears to be a complex integrated response regulated by both cytokines and the sympathetic nervous system, befitting a system integral to host survival. Both cytokine and α-adrenergic stimulation appear to alter the activity of several lipolytic enzymes. For example, Gram-negative infection has been shown in rodents to attenuate the activity of lipoprotein lipase in adipose tissue. Lipoprotein lipase is critical to hepatic lipid metabolism as once fatty acids reach the liver they can either be oxidized as an immediate energy source or reesterified to VLDL triglycerides and redistributed throughout the body. Since lipoprotein lipase cleaves fatty acids from triacylglycerols its inhibition results in a decreased ability to catabolize and thus clear circulating triglycerides. 11, 12 Interestingly, the effect of LPS on lipid metabolism is dose-dependent. Low dose LPS (100 ng/100 g body weight) produces hyperlipidemia through the stimulation of de novo hepatic fatty acid synthesis and lipolysis. Alternatively, the hyperlipidemia following high dose LPS (50 µg/100 g body weight) is due to decreased lipoprotein lipase activity and triglyceride (TG)-rich lipoprotein clearance by the liver. 13 Hormone sensitive lipase is another important lipolytic enzyme stimulated by systemic signals. The enzyme is activated in adipose tissue following LPS challenge and, like lipoprotein lipase, liberates fatty acids from circulating lipoproteins for uptake by the liver and skeletal muscle. A variety of hormones and growth factors regulate hormonesensitive lipase. In adipose tissue, the enzyme is inhibited by insulin and stimulated by catecholamines, cortisol and growth hormone. In addition to these lipolytic enzymes, cytokines and LPS also affect the activity of fatty acyl CoA synthetase, which catalyzes the conversion of long-chain fatty acids to esters. Memon et al. found that LPS and cytokines increase fatty acyl CoA synthetase activity in mitochondria, resulting in the re-esterification of free fatty acids for triglyceride production. 10 While our understanding of the inter-related effects of cytokines and the adrenergic nervous system on lipid metabolism is incomplete, the neuroendocrine response to infection clearly includes the elevation of plasma lipid levels. As stated earlier, this hyperlipidemia may simply represent the mobilization of energy stores to fuel the increased metabolic demands of the host. However, the capacity of lipoproteins to directly interact with bacterial, viral and fungal toxins certainly raises the possibility that these particles may function as more than lipid transporters.
LIPOPROTEINS BIND ENDOTOXIN
The hypothesis that TG-rich lipoproteins are components of an innate host immune response to infection resulted largely from observations made while studying chylomicron (CM) metabolism in humans approximately 12 years ago. It was noted that CM-enriched plasma samples could contain large quantities of LPS (> 10 pg LPS/mg lipoprotein TG) yet the LPS go undetected via standard Limulus assay. 14, 15 There are numerous plasma proteins capable of inhibiting the Limulus assay; but, since LPS also increases the production of TG-rich lipoproteins by the liver, we naturally questioned whether these two observations might not represent co-ordinated facets of a physiological defense mechanism.
As of 1988, most of the work examining the interaction between lipoproteins and LPS had focused on the cholesterol ester-rich HDL and LDL. Ulevitch et al. elegantly demonstrated the ability of HDL to bind LPS as part of a two-step process requiring serum. [16] [17] [18] This work had shown that initially serum appeared to disaggregate macromolecules of LPS. Subsequently the disaggregated LPS binds to HDL as evidenced by a decrease in the buoyant density of LPS when ultracentrifuged in a CsCl gradient. They further demonstrated that once LPS was bound to HDL its ability to induce fever, leukocytosis, and hypotension were dramatically reduced. 16, 17 The binding of LPS to HDL also prevented endotoxin-induced death in sensitized (adrenalectomized) mice. 16 Whereas Ulevitch and co-workers primarily focused on the interaction between HDL and LPS, Van Lenten et al. demonstrated that LDL could also bind LPS in much the same way. 19 LPS bound to LDL showed less toxicity to endothelial cells, although it was capable of initiating some components of the inflammatory response. 20 Importantly, previous studies that had examined a potential interaction between TGrich lipoproteins and LPS had shown that VLDL had much less ability to interact and form complexes with LPS than did the cholesterol-rich lipoproteins LDL and HDL. 17, 19 In fact, one study suggested that the reason for this difference might be that a lipoprotein's ability to interact with LPS is directly proportional to its cholesterol content. 19 In support of this conclusion, the investigators demonstrated that LPS binding was substantially increased in the TG-rich lipoprotein fraction from Watanabe heritable hyperlipidemic and cholesterol-fed rabbits as compared to controls. In these hyperlipidemic animals, the TG-rich lipoprotein fraction contained the cholesterol-enriched β-VLDL rather than the relatively cholesterol-poor VLDL present in the normolipidemic animals. The interaction of CM with LPS had not yet been examined.
Subsequently, it has been conclusively demonstrated that all lipoproteins can bind and neutralize the toxic effects of LPS, both in vitro 14, 15 and in vivo. 21 We showed that VLDL and CM could effectively protect mice against LPS-induced death. In addition, a commercially available TG-rich lipid emulsion used for parenteral nutrition in humans (Soyacal ® ) could also protect mice from LPS-induced toxicity. Since all of these lipid particles are large and rich in triglyceride, and contain little, or in the case of the lipid emulsion contain no, cholesterol, these results demonstrated that cholesterol was not essential or necessary for the interaction between lipoproteins and LPS to take place. Furthermore, the protective ability of all lipoproteins tested, including LDL and HDL, was directly dependent on the concentration of lipoprotein phospholipid present in the endotoxin-lipoprotein mixtures. [22] [23] [24] The principles of classical receptor-ligand binding do not govern the interaction between lipoproteins and LPS, as there is no 'LPS receptor' on the surface of lipoproteins. Rather, LPS is thought to simply dissolve into the phospholipid coat of the lipid particle. The nature of the lipoprotein-LPS 'binding' process thus predicts that the lipid A moiety is the region of the lipopolysaccharide macromolecule that inserts into the phospholipid monolayer of the lipoprotein. The lipid Aphospholipid interaction effectively reduces the bioavailability of LPS and thus neutralizes its toxic effects. The observation that all classes of lipoproteins and a synthetic lipid emulsion could protect against endotoxicity led us to presume that a lipid-glycolipid interaction must be at least partially responsible for this phenomenon. 21 Subsequently, Parker et al. examined the capacity of various lipoproteins and lipid particles to bind LPS from both smooth-and rough-type Gram-negative bacteria. 23 All lipid particles tested could inhibit LPS-dependent TNF-α production in whole human blood. Not only was a lipid A-phospholipid interaction central to the process, since both smooth-and roughtype LPS were neutralized, stepwise linear regression analysis of particle composition revealed that only phospholipid content was correlated to effectiveness. The concept that the phospholipid content of a lipid particle determines its capacity to bind and neutralize LPS is also supported by data from Cue et al. 24 These investigators determined the effect of various preparations of reconstituted human HDL on the response to intravenous LPS in rabbits. As predicted, the reconstituted HDL preparation with the highest phospholipid content yielded the greatest degree of protection.
While the capacity of TG-rich lipoproteins to bind and neutralize LPS can be accurately predicted by the phospholipid content of the lipid particles, additional protein constituents also play an important role in the process. Apolipoprotein E (apo E), consistent with its ability to facilitate the clearance of TG-rich lipoproteins by the liver, has been shown to both redirect LPS from Kupffer cells to hepatocytes, 25 and to protect against endotoxemia in rats. 26 Apo E knock-out mice are also more susceptible to LPS-induced lethality than controls, despite elevated plasma lipid levels. 27 Taken together, these observations identify apo E as a vital component of lipoprotein-mediated protection against LPS.
It has been recognized for more than 20 years that the interaction between LPS and lipoproteins is dependent on a plasma factor(s). 16, 21 While there are several plasma proteins that can interact with LPS, none have been more extensively studied than the cluster of differentiation antigen 14 (CD14) 28 and the acute phase reactant lipopolysaccharide binding protein (LBP). 29, 30 In concert, these two proteins dramatically impact both the sensitivity and overall magnitude of the host response to LPS.
CD14, a 55 kDa glycoprotein originally described in 1982, 31 has been identified as an important LPS effector molecule. Expressed on the surface of monocytes and macrophages at up to 50,000 molecules/cell, 32 the first indication that CD14 functions as a LPS receptor came from studies where anti-CD14 antibodies selectively prevented macrophage binding to LPS-coated erythrocytes. 33 It now appears that CD14 acts in combination with LBP as part of a high-affinity LPS recognition mechanism, facilitating macrophage activation by picogram quantities of LPS. 34 LPS and LBP appear to form a complex in serum with LPS subsequently transferred to CD14 before the toxic macromolecule ultimately triggers an intracellular signal. But, exactly how LPS binding to CD14 initiates an intracellular signal cascade is uncertain, especially since the protein lacks a transmembrane domain. 35 Instead, CD14 exist in two forms: one form is expressed by macrophages and other myeloid lineage cells and is anchored to the cell membrane through a glycosylphosphatidylinositol (GPI) linkage (mCD14), and another form that is soluble (sCD14). The soluble form of CD14 was originally described in 1985 due to its ability to block the staining of monocytes with anti-CD14 monoclonal antibody. 36 Present in the serum of normal individuals at a concentration of 4-6 µg/ml, 37 this 50-53 kDa glycoprotein enables various cells which do not express mCD14 to respond to low doses of LPS, including endothelial and epithelial cells. 38, 39 Apparently, these nonmyeloid cells have a protein on their surface that recognizes CD14-LPS complexes, as evidenced by PAGE analysis and the ability to inhibit the serum-dependent, LPS-mediated activation of endothelial cells via immunodepletion of CD14. [40] [41] [42] While many important aspects of LPS-induced cellular activation are at present unknown, CD14 undoubtedly plays a central role in the pathogenesis of Gram-negative sepsis.
Despite the initial prominence assigned to CD14, there is growing evidence that LBP also plays a significant role in the host response to LPS. In fact, LBP likely assumes an equally important function in the recognition and catabolism of circulating LPS. Endotoxins are amphipathic molecules that readily form micellar aggregates within aqueous environments. These aggregates react poorly with leukocytes and thus provoke very little in the way of a cellular response. LBP and sCD14 are two plasma proteins that dramatically enhance the host response to LPS. 43 LBP is a 60 kDa class 1 acute phase protein secreted by the liver in response to injury, trauma or infection. In addition, LBP shares structural and functional homology with a family of lipid transfer proteins (i.e. cholesterol ester transfer protein and phospholipid transfer protein), and a bactericidal leukocyte granule protein termed bacterial permeability increasing protein. [44] [45] [46] [47] Like CD14, LBP participates in the binding and transfer of LPS from micellar aggregates, 48, 49 bacterial membranes, 50 and mononuclear cells 51 to lipoproteins and other phospholipid/cell membranes (Fig. 1) . Specifically, LBP is thought to facilitate the binding of monomeric LPS by CD14 (membrane-bound and soluble forms) and thus promote LPS-induced cellular activation. Thus, circulating LPS may first react with LBP and in so doing define a core role for this acute phase reactant in the host response to Gram-negative sepsis. There is even evidence that LBP can directly transfer LPS to HDL independent of CD14. 52 The relative contribution of LBP versus CD14 to the catabolism of LPS remains the subject of intense research. But, clearly both proteins are essential to the binding of LPS by plasma lipoproteins 51, 53, 54 and thus integral components of the innate immune response to infection.
Additional insight into the mechanism of LPS signaling has been gained following the recent discovery of human homologues to the Drosophila Toll family of proteins. These cell-surface proteins, the homologues of which induce an innate immune response in plants and insects, appear to play a critical role in the mammalian host recognition and induction of gene expression by microbial lipids. Human Toll-like receptors (TLRs) appear to be expressed throughout the body with predominant expression within the spleen and peripheral blood leukocytes. 55 These cell surface proteins have an extracellular domain that contains 22 leucine-rich repeats, reminiscent of the LPS binding site of CD14, and a cytoplasmic domain homologous to that of the human IL-1 receptor. To characterize the function of these proteins, Medzhitov et al. transfected human lymphocytes with a dominant positive mutant. The transfected cells demonstrated activation of NF-κB, AP-1, and the induction of IL-1, IL-6 and IL-8 and thus linked TLRs to the host pro-inflammatory response. Subsequently, both genetic and additional experimental data have strongly postulated TLR4 as essential for the cellular recognition of and response to LPS. 56, 57 Three strains of mice (C3H/HeJ, C57BL/10ScCr and C57BL/10ScN) that are hyporesponsive to LPS and have an increased susceptibility to Gram-negative infection are now known to contain mutations in the tlr4 gene, each of which yields a dysfunctional TLR4 protein.
At least 10 mammalian TLRs have been identified, yet the precise ligands for these receptors are still being defined. In addition to TLR4, another Toll-like receptor TLR2 may also play a role in the host response to LPS.
While transfection of TLR2 confers LPS responsiveness to normally unresponsive cells, this protein is not essential to the host response since TLR2 -/mice still respond normally to LPS. [56] [57] [58] Thus, the exact role for the human TLRs in the host response to LPS and the exact specificity for the various proteins await further delineation. Interestingly, hepatocytes do not express either mCD14 or Toll-like proteins, and do not directly respond to sCD14-LPS complexes. Yet, the hepatic (acute phase) response to sepsis is directly mediated by the products of LPS-responsive myeloid and non-myeloid cells thereby highlighting a critical, albeit indirect role for LBP, CD14 and TLRs in the response of the liver to LPS.
LIPOPROTEINS PROTECT AGAINST ENDOTOXIN
Central to the hypothesis that TG-rich lipoproteins are components of an innate, non-adaptive host immure response to infection is their increased synthesis and secretion during sepsis and their capacity to protect against LPS-induced toxicity and death. Early evidence of the protective effect of lipoprotein binding on LPS toxicity came from the work of Ulevitch et al. They showed, in mice, that the capacity of HDL-bound LPS to induce fever, leukocytosis, hypotension and death was dramatically reduced compared to LPS alone. 16, 17 Subsequently, our laboratory demonstrated, also in a murine model of sepsis, that all lipoproteins along with a synthetic TG-rich lipid emulsion could protect against LPS-induced lethality. 21 Furthermore, we presented data supporting a role for endogenous TG-rich lipoproteins in the sequestration and neutralization of LPS in vivo in humans.
Over the past several years numerous investigators have provided additional evidence supporting a protective role for lipoproteins against endotoxicity. Despite employing different experimental models, each study shared the underlying hypothesis that elevated plasma lipoprotein levels are protective against LPS-mediated toxicity in vertebrates. In the various studies, hyperlipoproteinemia was induced via either the infusion of: (i) exogenous lipoproteins [59] [60] [61] ; (ii) synthetic emulsions 21, 59 ; (iii) recombinant lipoproteins [23] [24] [25] [62] [63] [64] [65] [66] ; (iv) genetic manipulation of the catabolic machinery for lipoproteins 54, 67 ; or (v) diet. 68 Regardless of the mechanism, elevations in the circulating level of any class of lipoprotein afforded protection against LPS as compared to normolipidemic controls. Furthermore, hypolipidemic animals have an increased susceptibility to LPS toxicity that is reversed with return of plasma lipid levels to the normal range. 61 Most of the evidence supporting a protective role for lipoproteins against LPS has understandably been generated using animal models of infection. In fact, there is precious little data examining this question in humans, and what data exist are contradictory and thus inconclusive. van der Poll et al. examined the effect of hypertriglyceridemia on the response to LPS in humans. 69 Whereas a TG-rich fat emulsion inhibited LPS-induced cytokine production in human whole blood in vitro, concurrent in vivo studies yielded the opposite conclusion. To examine the in vivo effects, volunteers were given a bolus injection of purified LPS (4 ng/kg, lot EC-5) halfway through either an infusion of a TG-rich emulsion versus dextrose 5% (controls). The lipid infusion produced a significant hypertriglyceridemia, yet the elevated lipid levels did not reduce the LPS-induced fever, leukocytosis or TNFα release compared to that measured in the control group. In addition, the lipid infusion apparently potentiated specific LPS responses, including the production of IL-6 and IL-8, neutrophil degranulation, and activation of the coagulation system. 70 Precisely what accounts for these discrepant results is uncertain. But, differences between the metabolism of lipoproteins versus lipid emulsions, [71] [72] [73] [74] and the kinetics of LPS binding by TGrich lipoproteins are likely, in part, responsible. 21, 54 The catabolism of TG-rich fat emulsions is complex and includes the generation of phospholipid-rich discoid particles termed lipoprotein-X. These abnormal lipid particles not only interfere with the clearance of endogenous TG-rich lipoproteins, 75 but also have a prolonged circulating half-life measured in days (24-60 h) 76 rather than the minutes required for the clearance of CM or VLDL. Accordingly, LPS bound to lipoprotein-X would be expected to remain in the circulation for days where it would be potentially available to activate cellular and non-cellular components of the immune system for an extended period.
Another important variable to consider is the kinetics of lipoprotein-LPS binding. This process is relatively slow in comparison to the binding of LPS by leukocytes. 23, 54 Consequently, we have customarily pre-incubated the lipoproteins and LPS together prior to administration to specifically facilitate their interaction. 21, 77, 78 In so doing, we selectively study the cellular or host response to lipoprotein-LPS complexes and not the kinetics of binding. The study design employed by van der Poll and colleagues necessarily examined both the kinetics of binding and the host response to LPS simultaneously. In contrast, our laboratory has examined the effect of TG-rich lipoproteins on the response to LPS in humans utilizing an experimental protocol modeled after our rodent studies. In these studies we have shown that both fasting and postprandial lipoproteins can inhibit the effects of LPS in humans. 79 Volunteers infused with LPS (4 ng/kg) that had been pre-incubated with either fasting or postprandial whole human blood yielded lower maximal temperatures, leukocyte counts, and plasma ACTH and TNF-α levels than controls injected with LPS in saline. While the overall clinical utility of lipids to combat Gram-negative infections remains an open question, these data in humans clearly parallel the results from numerous animal studies.
LIPOPROTEINS MODULATE THE HOST

RESPONSE TO ENDOTOXIN
TG-rich lipoproteins can bind LPS and thus modulate the host response to this toxic macromolecule by: (i) inhibiting the activation of macrophages, monocytes and other LPSresponsive cells; (ii) promoting the catabolism of LPS by the hepatic parenchymal cells; and (iii) inhibiting the response of hepatocytes to pro-inflammatory stimuli. Once introduced into the circulation, monomeric LPS is transferred to phospholipid-rich membranes through the action of LBP and CD14. The transfer or 'binding' process appears to involve the actual insertion of the lipid A domain of LPS into the phospholipid leaflet of the accepting cellular membrane or lipoprotein's surface coat. Since the lipophilic lipid A domain of the macromolecule is almost exclusively responsible for the toxic effects of LPS, the transfer process effectively masks this region thereby reducing its bioavailability. As predicted, lipoproteinbound LPS, with its lipid A domain rendered biologically invisible, is significantly less stimulatory to macrophages, 78 monocytes, [80] [81] [82] and other LPS-sensitive tissues.
In our effort to understand the molecular basis of the lipemia of sepsis, we hypothesized that TG-rich lipoproteins are components of an innate host immune response to infection. Furthermore, we postulated that the hepatic metabolism of TG-rich lipoproteins is part of a cytokinemediated, host homeostatic mechanism (Fig. 2) . Specifically, on exposure to LPS there is a cytokine-mediated increase in the hepatic synthesis and secretion of TG-rich lipoproteins, which when released act to 'scavenge' for circulating LPS. The resultant lipoprotein-bound LPS is then taken up by hepatocytes. Once internalized, the lipoprotein-bound LPS attenuates the response of hepatocytes to circulating pro-inflammatory cytokines, thereby downregulating the overall acute phase response. In support of this hypothesis, previous work has demonstrated that CM and VLDL can neutralize LPS and thus protect against endotoxic shock and lethality in rodent models of sepsis. 21, 77, 83 Also, CM increase the clearance of LPS by the liver while decreasing overall TNF-α production. The binding of LPS to CM more than doubled the amount of endotoxin taken up by the liver with most of the increased clearance observed due to uptake of the microbial toxin by hepatocytes rather than by Kupffer cells. 78 Interestingly, the internalized LPS appeared to dampen the response of hepatocytes to pro-inflammatory cytokines. Currently, we are detailing the molecular mechanism behind this potentially novel biological observation, including how CM-LPS complexes interact with hepatocytes and subsequently attenuate the response of these epithelial cells to cytokines. The postulated series of events whereby a foreign molecule (LPS) serves to both trigger and attenuate a programmed cellular stress response is unprecedented. Understanding how lipoprotein-bound LPS influences the activation of cytoplasmic signaling molecules within hepatocytes is critical to our understanding of the host response to infection.
Utilizing an in vitro system, we have confirmed and extended the in vivo observations showing that CM-LPS complexes can exert an anti-inflammatory effect on hepatocytes. 78 Recent data demonstrate that the pretreatment of hepatocytes with CM-bound LPS attenuates NO production by dampening cytokine-induced NF-κB activation. As shown in Figure 3 , hepatocytes pretreated with CM-LPS complexes exhibit a significant reduction in cytokine-induced NO production. 84 Neither LPS nor CM alone have any significant effect on NO production, yet the combination reduces the detectable nitrite yield by approximately 60%. Since CM-bound LPS pretreatment attenuates the response of hepatocytes to a combination of different 426 Harris, Gosnell, Kumwenda Fig. 2 . Proposed modulation of the host inflammatory response by triglyceride (TG)-rich lipoproteins. Once endotoxin (1) enters the circulation it (2) rapidly stimulates macrophages (myeloid) and endothelial (nonmyeloid) cells to (3) produce numerous soluble mediators of inflammation, including TNF-α, IL-1β and nitric oxide. LPS triggers cell activation through a variety of proteins, including lipopolysaccharide binding protein (LBP), and membrane-bound and soluble forms of CD14 (mCD14). Interestingly, the liver is not directly stimulated by circulating LPS, but is instead (4) activated by the cytokine products of LPS-responsive cells. Consequently, the liver responds to the endotoxic challenge with a dramatic alteration in hepatic protein synthesis termed 'the acute phase response'. This cytokine-mediated change in gene expression includes (5) the increased production and release of TG-rich lipoproteins (VLDL), and LBP, a 60 kDa protein with lipidtransfer activity capable of (6) 'binding' LPS to lipoproteins. We postulate that TG-rich lipoproteins modulate the host response to LPS by first, the formation of lipoprotein-LPS complexes which 'scavenge' that LPS still in circulation, thus neutralizing its toxicity. Secondly, the complexes are (7) cleared by the liver in a manner that dampens the hepatic response to further cytokine stimulation, thereby modulating the acute phase response. (sCD14: soluble CD14.) Fig. 3 . Pretreatment with chylomicron-endotoxin complexes reduces cytokine-stimulated nitric oxide (NO) production by rat hepatocytes. Cultured hepatocytes were pretreated with endotoxin (LPS, 1 µg/ml), chylomicrons (CM, 5 mg TG/ml), chylomicron-endotoxin complexes (CM-LPS, 5 mg TG/ml) or medium alone (control) for 2 h. Subsequently, the cells were washed and recovered in fresh medium for approximately 18 h. The cells then were exposed to a mixture of TNF-α (500 U/ml), IL-1β (100 U/ml) and IFN-γ (100 U/ml) for 24 h and NO production determined. The data represent the mean SD of four separate experiments normalized to the response of cytokine-stimulated hepatocytes that were not pretreated (control cells). *P < 0.001 versus control. cytokines, we postulated that NF-κB, a transcription factor known to be activated by pro-inflammatory cytokines, might represent the potential site of inhibition. Additional studies demonstrate that CM-LPS complexes can inhibit the cytokine-induced activation of NF-κB in rat hepatocytes ( Fig. 4) . Specifically, cells pretreated with CM-LPS contained significantly less activated NF-κB than did those cells pretreated with either LPS or CM alone. 84 Collectively, these data show that CM-bound LPS exerts an inhibitory effect on the cytokine-induced activation of NF-κB in rat hepatocytes. The anti-inflammatory effect of CM-LPS complexes likely represents an endogenous mechanism by which the host regulates the hepatic acute phase response. These data also indicate that LPS may serve to both initiate and regulate the host inflammatory response to Gram-negative infection. The observed series of events, whereby this toxic macromolecule serves to both initiate and terminate a programmed cellular stress response, suggests a novel homeostatic pathway for regulation of the acute phase response.
CONCLUSIONS
In conclusion, LPS elicits dramatic changes in the host, including the increased synthesis and secretion of TG-rich lipoproteins by the liver. This LPS-induced hyperlipoproteinemia, the 'lipemia of sepsis', was customarily thought to represent the mobilization of lipid stores to fuel the host response to infection. But, since lipoproteins also have the capacity to bind and neutralize LPS, we hypothesize that TG-rich lipoproteins represent agents of an innate, nonadaptive host immune response. Interestingly, the LPS-lipoprotein binding process entails the insertion of the lipophilic lipid A domain of endotoxin into the phospholipid surface of the accepting lipoprotein and is facilitated by CD14 and LBP, itself an acute phase protein. Once inserted, the ability of the lipid A moiety to stimulate LPSresponsive cells and tissues is greatly reduced. Furthermore, the catabolism of LPS subsequently mirrors that of the lipoprotein with which it is associated. When LPS is bound to a TG-rich lipoprotein it is rapidly cleared from the circulation by hepatocytes. Subsequently, the internalized lipoprotein-LPS complex exerts an anti-inflammatory effect, attenuating the cytokine-mediated activation of NF-κB and thus serves to regulate the acute phase response. Ultimately a better understanding of how TG-rich lipoproteins modulate the host response to LPS could yield novel biological insights with important clinical implications. Fig. 4 . Cytokine mediated NF-κB activation is reduced in cells pretreated with chylomicron-endotoxin complexes. Cultured hepatocytes were pretreated with LPS (1 µg/ml), CM (5 mg TG/ml), CM-LPS (5 mg TG/ml) or medium alone (control) for 2 h. Subsequently, the cells were washed, recovered for approximately 22 h and then exposed to a mixture of TNF-α (500 U/ml), IL-1β (100 U/ml) and IFN-γ (100 U/ml) for 30 min. Unstimulated, control cells (control [-]) served as one negative control. NF-κB activity was analyzed via EMSA. Shown is a representative autoradiograph along with the densitometric analysis of the gel data from three separate experiments. *P < 0.03 versus control. (SCOB: specific competitor of oligonucleotide binding.)
